



## Site master file SUP-ICU

EudraCT number 2015-000318-24

### Table of contents

- 1) Protocol and trial synopsis
  - a) Approved protocol
  - b) Approved amendments
  - c) Trial synopsis
  
- 2) CRF
  
- 3) Trial participants
  - a) Delegation- and signature log
  - b) Training log
  - c) Curriculum Vitae for all personnell
  
- 4) Approvals and correspondence
  - a) The Danish Health and Medicines Authority
  - b) EudraCT
  - c) The Committees on Health Research Ethics
  - d) The Danish Data Protection Agency (Datatilsynet)
  - e) National and local approvals
  - f) Annual Safety Report
  
- 5) Collaboration agreement
  - a) Collaboration agreement between Sponsor and site
  - b) Approval from head of department
  - c) Other relevant contracts
  
- 6) Financial affairs
  - a) Case money
  - b) Patient insurances (where relevant)

- 7) Information to participants
  - a) Patient information
  - b) Consent forms
  
- 8) Co-enrolment og substudies
  - a) Co-enrolment form
  - b) Quality criteria for substudies
  - c) Substudy proposal form
  
- 9) Trial documents
  - a) Trial instructions
    - i) Eligibility
    - ii) Screening and randomisation
    - iii) Trial medication
    - iv) eCRF
    - v) SAR/SUSAR
  - b) Pocket cards, documents for a notice board in the department
    - i) Trial medication for notice board
    - ii) Inclusion and exclusion criteria for notice board
    - iii) Trial synopsis for notice board
    - iv) Pocket cards
    - v) Leaflet for clinicians/nurses
    - vi) Sign for bed
    - vii) Identification log
  - c) Educational material (power point presentations)
    - i) Background
    - ii) Screening and randomisation
    - iii) Trial medication
    - iv) Data entry
    - v) Withdrawal
    - vi) SAR/SUSAR and undblinding
    - vii) Information for nurses
  
- 10) Trial medication
  - a) Labels
  - b) Summary of product characteristics
  - c) Drug disposal form

- d) Receipt of trial medication
- e) Instruction for temperature logger

11) Laboratory tests

12) Primary data source

13) Communication

- a) Contact details – Steering Committee
- b) Contact details – Denmark, Finland, Netherlands, Norway, UK, Italy, Switzerland
- c) Note to file send to Sponsor
- d) Note to file received from Sponsor
- e) Other correspondances between Sponsor and site(s)
- f) News letters
- g) Investigator meeting

14) Serious adverse reactions and suspected unexpected serious adverse reactions

- a) SAR/SUSAR form
- b) Documentation for reporting of SAR/SUSAR

15) GCP unit

- a) Contacts (monitors/GCP units)
- b) Monitoring visits
- c) Monitoring reports
- d) Monitoring plan
- e) Approval of trial initiation
- f) Correspondance with the monitor (e.g. GCP-unit)

16) Trial completion